← 홈

Catalyst · Landscape

향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS

파이프라인 Phase 분포

큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.

Preclinical
132
Phase 1
491
Phase 2
979
Phase 3
293
Approved
134

Catalyst target · modality

향후 6개월 catalyst 6건 · 타깃·모달리티 분포

ADC 3Antibody 3
PD-L1
3
Nectin-4
2
HER2
1

향후 6개월 Catalyst(6 / 80)

활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시

완료 예정프로그램PhaseStatusEndpoint신뢰도NCT
2026년 9월Tecentriq (atezolizumab)Antibody · PD-L1Phase 1Active, not recruitingFeasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.; Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.보통NCT03228537
2026년 9월Padcev (enfortumab vedotin)ADC · Nectin-4N/ARecruitingChange from Baseline in Circulating EV Concentration신뢰 높음NCT07558447
2026년 9월Disitamab Vedotin (RC48)ADC · HER2Phase 1, Phase 2Recruitingdose-limiting toxity; ORR（Objective Response Rate）보통NCT05403242
2026년 9월Tecentriq (atezolizumab)Antibody · PD-L1Phase 2Active, not recruitingNumber of patients who experience complete or partial tumor response신뢰 높음NCT03526432
2026년 9월Tecentriq (atezolizumab)Antibody · PD-L1Phase 2Active, not recruitingFailure-free Rate at 2 Years보통NCT04262154
2026년 9월Padcev (enfortumab vedotin)ADC · Nectin-4Phase 2Active, not recruitingCohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment; Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment신뢰 높음NCT04225117
  • 2026년 9월보통
    Tecentriq (atezolizumab)

    Antibody · PD-L1 · Phase 1

    Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.; Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.

    NCT03228537
  • 2026년 9월신뢰 높음
    Padcev (enfortumab vedotin)

    ADC · Nectin-4 · N/A

    Change from Baseline in Circulating EV Concentration

    NCT07558447
  • 2026년 9월보통
    Disitamab Vedotin (RC48)

    ADC · HER2 · Phase 1, Phase 2

    dose-limiting toxity; ORR（Objective Response Rate）

    NCT05403242
  • 2026년 9월신뢰 높음
    Tecentriq (atezolizumab)

    Antibody · PD-L1 · Phase 2

    Number of patients who experience complete or partial tumor response

    NCT03526432
  • 2026년 9월보통
    Tecentriq (atezolizumab)

    Antibody · PD-L1 · Phase 2

    Failure-free Rate at 2 Years

    NCT04262154
  • 2026년 9월신뢰 높음
    Padcev (enfortumab vedotin)

    ADC · Nectin-4 · Phase 2

    Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment; Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment

    NCT04225117